JP Morgan splashes into the life sciences, tapping Stephen Squinto to run venture team with high-powered advisors
This morning we’re getting another clear sign of just how much private equity has come to love biopharma during these stressful post-boom times and battered valuations. And nothing says “I love you” quite as much as billions in backing.
JP Morgan is the latest private equity player to get into the game — and they’re fielding a pro team with high visibility.
Alexion co-founder and ex-OrbiMed investor Stephen Squinto is leading the new venture group, promising to play advisor as well as financier to the life sciences companies they back. Life Sciences Private Capital is taking the field to go after “early and growth stage healthcare companies” with a special focus on drugs and tech. Key areas include genetics, oncology, neurodegeneration, rare diseases, AI and ML, metabolics and psychology.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.